The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB / IIIA glycoprotein in reducing adverse clinical events in patients suffering an ST-segment elevation myocardial infarction undergoing primary angioplasty, at the expense of increase in the rate of acute stent thrombosis. This study included 2194 patients undergoing an...

While the use of intravascular ultrasound (IVUS) during coronary intervention proved useful in multiple studies, there is limited evidence in the literature regarding its use in specifically in chronic total occlusions. The IVUS may help guide in recognizing the true lumen and better distal positioning, better coverage of stent, an optimal apposition and expansion, diagnose...

This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2: 1 (Absorb / Xience) with de novo lesions in native coronary arteries with a reference diameter between 2.25 and 3.8 mm estimated by quantitative angiography. All the patients underwent IVUS and...

This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction...

This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5 years were included. The rate of target lesion (composite of cardiac death, myocardial infarction and target lesion revascularization) was 3.9% at one year and 5.1% at 2 years. Long-term clinical performance...

TRYTON is a cobalt chromium device specifically dedicated for bifurcation lesions to be implanted in the side branch. Circumflex artery is the major lateral branch fund the coronary tree. Between 2008 and 2011 this work included 52 patients with left main coronary unprotected lesions who underwent angioplasty with drug-eluting stent in the coronary trunk left...

Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom...

This study randomized 2:1 – 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and...

The PARIS registry was a prospective observational study in 5018 patients undergoing coronary angioplasty with stent implantation in 15 centers. Three categories were prespecified in the discontinuation of dual antiplatelet therapy: 1) discontinuation for medical guidance, 2) transient discontinuation for less than 15 days for surgery and 3) permanent abandonment of it by non-adherence or...

The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with  biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and  the new device reached the non-inferiority with a MACE rate of 11.2% for...